Related references
Note: Only part of the references are listed.Sa447 RESOLUTION IN GENE SIGNATURES ASSOCIATED WITH INFLAMMATORY IMMUNE CELL INFILTRATES, ACTIVATED FIBROBLASTS AND EPITHELIAL RECOVERY IN TNF-NAIVE AND TNF-IR UC PATIENTS TREATED WITH ETROLIZUMAB
Courtney Schiffman et al.
GASTROENTEROLOGY (2021)
The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies
Iris Dotan et al.
MEDICINAL RESEARCH REVIEWS (2020)
Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus
Silvio Danese et al.
DIGESTIVE DISEASES (2019)
Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
Lieven Pouillon et al.
BMC MEDICINE (2019)
Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
Xiaohui Wei et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease
M. T. Tang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
Mark G. Ward et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary
Peter D. R. Higgins et al.
JOURNAL OF PATIENT-REPORTED OUTCOMES (2018)
Overcoming disease-specific matrix effect in a clinical pharmacokinetic assay using a microfluidic immunoassay technology
Kathi Williams et al.
BIOANALYSIS (2017)
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab
Konstantinos Papamichael et al.
JOURNAL OF CROHNS & COLITIS (2016)
Long-term outcomes of colectomy surgery among patients with ulcerative colitis
Carl Brown et al.
SPRINGERPLUS (2015)
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Severine Vermeire et al.
LANCET (2014)
Adverse events in IBD: to stop or continue immune suppressant and biologic treatment
Leon P. McLean et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2014)
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
Paul J. Rutgeerts et al.
GUT (2013)
A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes
E. G. Stefanich et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Female Gender and Surgery Impair Relationships, Body Image, and Sexuality in Inflammatory Bowel Disease: Patient Perceptions
Kate R. Muller et al.
INFLAMMATORY BOWEL DISEASES (2010)
Stratified Wilson and Newcombe Confidence Intervals for Multiple Binomial Proportions
Xin Yan et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2010)
General Multistage Gatekeeping Procedures
Alex Dmitrienko et al.
BIOMETRICAL JOURNAL (2008)
Share Paper
